| Monoclonal antibody | |
|---|---|
| Type | Fab' fragment |
| Source | Mouse |
| Target | NCA-90 (granulocyte cell antigen) |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody [1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells. [2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation [3]
It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis [4] [5] but has not secured FDA approval for use in American markets. [6] In addition to approved uses, LeukoScan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection. [7] [8] [9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018. [10]
